Compare Adaptive Biotechnologies Corp (ADPT) vs 8x8 Inc (EGHT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs 8x8 Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.04 (market cap $3.33B), while 8x8 Inc trades at $2.06 (market cap $279.31M). The key difference: Adaptive Biotechnologies Corp is far larger — about 11.9× 8x8 Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | EGHT | |
|---|---|---|
Market Cap | $3.33B | $279.31M |
Sector | Health | Technology |
52-Week High | $22.37 | $2.76 |
52-Week Low | $10.24 | $1.59 |
Enterprise Value | $3.19B | $556.99M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
EGHT (8x8, Inc.) trades at $1.94, up 6.01% today, with a bullish technical signal despite bearish moving averages. The company shows strong revenue growth with Q4 2026 earnings beating estimates at $0.11 EPS versus $0.07 expected. Recent news highlights AI product launches and industry recognition, including being named a 2026 MetriStar Top Provider for CPaaS. However, the company reported a net loss of $27.21 million for 2025, though projections show potential profitability improvement in 2026.
The outlook remains cautiously optimistic with analyst consensus showing 39% buy ratings but mixed technical indicators. Key opportunities include continued AI product adoption and revenue growth momentum, while risks center on profitability challenges, high debt levels, and competitive pressures in the communications platform market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →
